The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
Open accessAbstract
The economic burden of cancer in the United States is substantial and expected to increase significantly in the future because of expected growth and aging of the population and improvements in survival as well as trends in treatment patterns and costs of care following cancer diagnosis. In this article, we describe measures of the economic burden of cancer and present current estimates and projections of the national burden of cancer in the United States. We discuss ongoing efforts to characterize the economic burden of cancer in the United States and identify key areas for future work including developing and enhancing research resources, improving estimates and projections of economic burden, evaluating targeted therapies, and assessing the financial burden for patients and their families. This work will inform efforts by health care policy makers, health care systems, providers, and employers to improve the cancer survivorship experience in the United States. Cancer Epidemiol Biomarkers Prev; 20(10); 2006–14. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“For example, colorectal cancer patients carrying KRAS mutations do not respond to treatment with cetuximab or panitumumab (54), and by restricting the use of cetuximab to patients without theKRASmutations, the incremental cost-effectiveness ratio is more favorable (55).”
BackgroundProjections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Self-citationMedical Bankruptcy in the United States, 2007: Results of a National Study
Himmelstein, D. U., Thorne, D., Warren, E., & Woolhandler, S. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.012 · Cited by 805
Cost of Care for Elderly Cancer Patients in the United States
Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L., Topor, M., Meekins, A., & Brown, M. L. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn103 · Cited by 700
Self-citationEstimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data
Brown, M. L., Riley, G. F., Schussler, N., & Etzioni, R. (2002) · Medical Care · doi:10.1097/00005650-200208001-00014 · Cited by 612
Burden of Illness in Cancer Survivors: Findings From a Population-Based National Sample
Yabroff, K. R., Lawrence, W. F., Clauser, S., Davis, W. W., & Brown, M. L. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh255 · Cited by 596
Self-citationShih, Y.-C. T., Xu, Y., Cormier, J. N., Giordano, S., Ridner, S. H., Buchholz, T. A., Perkins, G. H., & Elting, L. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3517 · Cited by 489
Geographic Variation in the Treatment of Localized Breast Cancer
Farrow, D. C., Hunt, W. C., & Samet, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261701 · Cited by 477
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 436
Cited by
Islami, F., Goding Sauer, A., Miller, K. D., Siegel, R. L., Fedewa, S. A., Jacobs, E. J., McCullough, M. L., Patel, A. V., Ma, J., Soerjomataram, I., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21440 · Cited by 1,610
US spending on personal health care and public health, 1996-2013.
Dieleman, J. L., Baral, R., Birger, M., Bui, A. L., Bulchis, A., Chapin, A., Hamavid, H., Horst, C., Johnson, E. K., Joseph, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16885 · Cited by 1,044
Cheville, A. L., Moynihan, T., Herrin, J., Loprinzi, C., & Kroenke, K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0011 · Cited by 143
Empowerment of Cancer Survivors Through Information Technology: An Integrative Review
Groen, W. G., Kuijpers, W., Oldenburg, H. S., Wouters, M. W., Aaronson, N. K., & van Harten, W. H. (2015) · Journal of Medical Internet Research · doi:10.2196/jmir.4818 · Cited by 126
Multimodal Deep Learning Approaches for Precision Oncology: A Comprehensive Review
Yang, H., Yang, M., Chen, J., Yao, G., Zou, Q., & Jia, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae699 · Cited by 115
Metadata
- Authors
- Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2011-10-01
- Volume
- 20
- Issue
- 10
- Pages
- 2006-2014
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2140811091
- Cited by
- 503
- References
- 58
- FWCI
- 36.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. https://app.cochat.ai/papers/10.1158/1055-9965.epi-11-0650
- The paper
- Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011). Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-11-0650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.